INTORSECT, 2014 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of temsirolimus versus sorafenib in Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib

        Z

NCT00474786    J Clin Oncol 2014;32:760-7  



Studied treatment temsirolimus 25 mg once weekly by intravenous (IV) infusion
Control treatment sorafenib 400 mg PO twice daily



Patients Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
Group sizes259 / 253
treatment line line 2



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint PFS Design



EndpointX1N1X0N0TE95% CI PFS - 259 - 253 0,87[0,71; 1,07] OS - 259 - 253 1,31[1,05; 1,63]0,22,01,0

Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:760-7     [PMID: 24297950]   link to pdf   add to Mendeley  

ClinicalTrial.gov record NCT00474786



Registering number NCT00474786 (see trial on clinicaltrials.gov)
Code Name